BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 23548965)

  • 21. Letter to the editor. Women with HER2-positive metastatic breast cancer have significantly longer survival after diagnosis of brain metastasis(BM) than those with HER2-negative disease.
    Kilickap S; Arslan C
    Am J Clin Oncol; 2009 Apr; 32(2):226. PubMed ID: 19346820
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical outcomes and breast cancer subtypes in patients with brain metastases.
    Kwon HC; Oh SY; Kim SH; Lee S; Kwon KA; Choi YJ; Cho GJ; Kim YS; Lee M; Lee JH; Kim DC; Lee HS; Cho SH; Kim HJ
    Onkologie; 2010; 33(4):146-52. PubMed ID: 20389140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
    Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients.
    Paluch-Shimon S; Ben-Baruch N; Wolf I; Zach L; Kopolovic J; Kruglikova A; Modiano T; Yosepovich A; Catane R; Kaufman B
    Am J Clin Oncol; 2009 Oct; 32(5):504-8. PubMed ID: 19564785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.
    Synnestvedt M; Borgen E; Russnes HG; Kumar NT; Schlichting E; Giercksky KE; Kåresen R; Nesland JM; Naume B
    Acta Oncol; 2013 Jan; 52(1):91-101. PubMed ID: 22934555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors affecting the prognosis of breast cancer patients with brain metastases.
    Saip P; Cicin I; Eralp Y; Kucucuk S; Tuzlali S; Karagol H; Aslay I; Topuz E
    Breast; 2008 Oct; 17(5):451-8. PubMed ID: 18455400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.
    Arvold ND; Oh KS; Niemierko A; Taghian AG; Lin NU; Abi-Raad RF; Sreedhara M; Harris JR; Alexander BM
    Breast Cancer Res Treat; 2012 Nov; 136(1):153-60. PubMed ID: 22968656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gamma Knife radiosurgery for brain metastases from primary breast cancer.
    Kased N; Binder DK; McDermott MW; Nakamura JL; Huang K; Berger MS; Wara WM; Sneed PK
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1132-40. PubMed ID: 19345514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distant metastasis in triple-negative breast cancer.
    Tseng LM; Hsu NC; Chen SC; Lu YS; Lin CH; Chang DY; Li H; Lin YC; Chang HK; Chao TC; Ouyang F; Hou MF
    Neoplasma; 2013; 60(3):290-4. PubMed ID: 23373998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of triple-negative phenotype on prognosis of patients with breast cancer brain metastases.
    Xu Z; Schlesinger D; Toulmin S; Rich T; Sheehan J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):612-8. PubMed ID: 22436795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain metastases as late breast cancer relapse. Single institution experience and review of the literature.
    Tomasevic Z; Radosevic-Jelic Lj; Jovanovic D; Milovanovic Z; Tomasevic ZM; Jelic S; Borojevic N
    J BUON; 2009; 14(2):225-8. PubMed ID: 19650170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
    Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
    Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer subtypes and outcomes of central nervous system metastases.
    Arslan UY; Oksuzoglu B; Aksoy S; Harputluoglu H; Turker I; Ozisik Y; Dizdar O; Altundag K; Alkis N; Zengin N
    Breast; 2011 Dec; 20(6):562-7. PubMed ID: 21871802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.